Ignite Creation Date:
2024-05-06 @ 5:23 PM
Last Modification Date:
2024-10-26 @ 2:28 PM
Study NCT ID:
NCT05296278
Status:
RECRUITING
Last Update Posted:
2024-01-10
First Post:
2022-03-16
Brief Title:
Efficacy and Biomarker Explanation of IBI-323 Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC
Sponsor:
Hunan Province Tumor Hospital
Organization:
Hunan Province Tumor Hospital
Organization Data
Organization:
Hunan Province Tumor Hospital
Class:
OTHER
Study ID:
REVERSE
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Hunan Province Tumor Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
Yongchang Zhang
Responsible Party Title:
Director Head of Medical Oncology Principal Investigator Clinical Professor
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Hunan Province Tumor Hospital
Old Name:
None
Old Organization:
None